ARTICLE | Clinical News
Viela publishes Phase Ib data for CD40L antagonist in RA
April 25, 2019 7:11 PM UTC
Viela said the highest two doses of VIB4920 (formerly MEDI4920) significantly reduced disease activity in a Phase Ib trial to treat rheumatoid arthritis.
Data were published in Science Translational Medicine. Viela first reported data from the trial in October at the American College of Rheumatology and the Association of Rheumatology Health Professionals meeting in Chicago...
BCIQ Target Profiles